Abstracts tagged "Outcome measures"

Abstract Number: 1173 • ACR Convergence 2020
No Disease Progression After 36 Months Follow up in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Maria Teresa Terreri⁵, Edoardo Marrani⁶, Tadej Avcin⁷, Maria Katsicas⁸, Dana Nemcova⁹, Maria Jose Santos¹⁰, Jürgen Brunner¹¹, Tilmann Kallinich¹², Mikhail Kostik¹³, Kirsten Minden¹⁴, Anjali Patwardhan¹⁵, Kathryn Torok¹⁶ and Nicola Helmus¹⁷, ¹Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ²German Rheumatism Research Center, Berlin, Germany, ³PRINTO, Istituto Giannina Gaslini, Genova, Italy, ⁴Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁵Federal University of São Paulo, São Paulo, Brazil, ⁶University of Florence, Firenze, Italy, ⁷Ljubljana University Medical Centre, Ljubljana, Slovenia, ⁸Hospital de Pediatria, Buenos Aires, Argentina, ⁹General University Hospital, Prague, Czech Republic, ¹⁰Hospital Garcia de Orta, Almada, Portugal, ¹¹Tirol Kliniken, Innsbruck, Innsbruck, Austria, ¹²Charite, Berlin, Germany, ¹³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁴Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁵University of Missouri, Columbia, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. Longitudinal prospective follow up data of…
Abstract Number: 1714 • ACR Convergence 2020
Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Description of disease activity status in patients with rheumatoid arthritis (RA) at fixed points in time modelled as continuous (e.g. number of swollen joints…
Abstract Number: 1902 • ACR Convergence 2020
Determinants of Physician Global Assessment and Influence of Contextual Factors in Early Axial Spondyloarthritis
Fumio Hirano¹, Robert Landewé², Floris van Gaalen³, Désirée van der Heijde⁴, Cecile Gaujoux-Viala⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, ²Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ³Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: In rheumatic and musculoskeletal diseases, physician global assessment (PhGA) is a major factor of treatment decision. However, it is not well-known which disease manifestations…
Abstract Number: 0168 • ACR Convergence 2020
Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
Uwe Pleyer¹, Salem Almutairi², Conor Murphy³, Rola Hamam⁴, Karina Julian⁵, Shereen Hammad⁶, Orsolya Nagy⁷, Zohar Habot-Wilner⁸, Zsuzsanna Szepessy⁹, Yan Guex-Crosier¹⁰ and Sofia Androudi¹¹, ¹Charité Universitätsmedizin Berlin, Klinik für Augenheilkunde, Berlin, Germany, ²Al-Bahar Ophthalmology Center - Al-Sabah Hospital, Kuwait City, Kuwait, ³Royal Victoria Eye & Ear Hospital, Dublin, Ireland, ⁴American University of Beirut, Beirut, Lebanon, ⁵Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁶AbbVie Biopharmaceuticals GmbH, Dubai, United Arab Emirates, ⁷AbbVie Kft, Budapest, Hungary, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Semmelweis University, Budapest, Hungary, ¹⁰Jules-Gonin Eye Hospital, Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland, ¹¹University of Thessaly, Larissa, Greece
Background/Purpose: VISUAL clinical trials demonstrated efficacy and safety of adalimumab (ADA) in patients with active and inactive non-infectious, intermediate, posterior, or panuveitis (NIIPPU).1-3 The purpose…
Abstract Number: 0339 • ACR Convergence 2020
Is Sex-adjusted Treatment in Early-PsA Justified?
Evangelia Passia¹, Jolanda Luime¹, Marc Kok², Ilja Tchetverikov³, Marijn Vis⁴, Fouchia Fodili⁵, Yvonne Ruiterman⁶ and Lindy-Anne Korswagen⁷, ¹Erasmus MC, Rotterdam, ²Maasstadziekenhuis, Rotterdam, ³Albert Schweitzer Ziekenhuis, Dordrecht, ⁴Erasmus UMC, Rotterdam, Netherlands, ⁵RZWN, Roosendaal, ⁶HAGA ziekenhuis, Den Haag, ⁷Franciscus Gasthuis, Rotterdam
Background/Purpose: According to existing knowledge, the prevalence of psoriatic arthritis (PsA) is equal in men and women, however, women experience a higher burden of disease…
Abstract Number: 0755 • ACR Convergence 2020
Exploring the Significance of Anti-Nuclear Antibody Positivity in the Medical Management of Patients with Rheumatoid Arthritis
Sujaytha Paknikar¹, Cynthia Crowson², John Davis¹ and Uma Thanarajasingam¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: ANA testing has been a well-established screening tool for autoimmune conditions such as SLE. Current practice for classification of RA does not include ANA…
Abstract Number: 1212 • ACR Convergence 2020
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)
Peter Taylor¹, Bryan Downie², Emon Elboudwarej², Sam Kim², Angie Hertz², Amer Mirza², Jeff Siegel³, Rachael Hawtin² and Jinfeng Liu², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active RA. Previously, we…
Abstract Number: 1715 • ACR Convergence 2020
Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Glen Hazlewood², Susan Bartlett³, Marie-France Valois³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin⁹, Vivian Bykerk¹⁰ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹Canadian Early Arthritis Cohort Study, Montreal, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec, Canada, ⁵Universite de Sherbrooke, Sherbrooke, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ⁸Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Early diagnosis and rapid initiation of DMARDs following a treat-to-target approach have made remission a realizable goal for many persons living with RA. Despite…
Abstract Number: 1960 • ACR Convergence 2020
Cost-effectiveness of Surgical and Non-Surgical Weight Loss Programs for Morbidly Obese Patients with Knee Osteoarthritis
Valia Leifer¹, Jeffrey Katz², Faith Selzer³, Tuhina Neogi⁴, Jamie Collins⁵ and Elena Losina², ¹The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, ²Harvard Medical School / The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA, ³The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Amesbury, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA
Background/Purpose: Growing numbers of knee osteoarthritis (KOA) patients are morbidly obese (BMI ≥ 35 kg/m2). Evolving evidence suggests weight reduction may delay the structural progression…
Abstract Number: 0169 • ACR Convergence 2020
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Juliette Yedimenko¹, Jessica Walsh², Alexis Ogdie³, Yuxuan Jin¹, Soumya Reddy⁴, Jose Scher⁵ and M. Elaine Husni¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, New York City
Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…
Abstract Number: 0344 • ACR Convergence 2020
Use of the BASDAI in Psoriatic Arthritis Patients with and Without Axial Disease
Soumya Reddy¹, M. Elaine Husni², Jose Scher³, Ethan Craig⁴, Alexis Ogdie⁴ and Jessica Walsh⁵, ¹NYU School of Medicine, New York, NY, ²Cleveland Clinic, Cleveland, OH, ³NYU School of Medicine, New York City, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is increasingly being used to assess the activity of axial disease in patients with psoriatic arthritis…
Abstract Number: 0830 • ACR Convergence 2020
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³, Edward C Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
Abstract Number: 1236 • ACR Convergence 2020
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
Sebastian Unizony¹, Joseph Dang², Jian Han³, Margaret Michalska² and Jennie H. Best², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, ³Genentech, South San Francisco, CA
Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
Abstract Number: 1717 • ACR Convergence 2020
Impact of Treatments on Favorable Outcome over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort
Joanna Kedra¹, David Hajage¹, Alexandre Lafourcade¹, Bernard Combe², Maxime Dougados³ and Bruno Fautrel⁴, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ²University of Montpellier, Montpellier, France, ³Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁴Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Long-term observational studies on the prediction of favorable outcome (FO) in rheumatoid arthritis (RA) have mostly considered patients baseline characteristics and have rarely evaluated…
Abstract Number: 1983 • ACR Convergence 2020
Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Natalie Shiff¹, Peter Shrader², Colleen Correll³, Anne Dennos⁴, Thomas Phillips² and Timothy Beukelman⁵, ¹Florida, Gainesville, FL, ²Duke University, Durham, ³University of Minnesota, Minneapolis, MN, ⁴Duke University, Durham, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To describe data-derived 2-year trajectories of disease activity in patients with recently diagnosed juvenile idiopathic arthritis (JIA) as measured by the clinical Juvenile Arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].